Full-Time
Finance Manager
FP&a
Posted on 1/12/2026
HeartFlow
501-1,000 employees
Non-invasive cardiac imaging to guide treatment
Compensation Overview
$150k - $185k/yr
San Francisco, CA, USA + 1 more
More locations: Santa Rosa, CA, USA
Hybrid
Hybrid in-office requirement; on-site in SF or Santa Rosa, CA.
 Finance & Banking (1) |
|---|
- Bachelor's degree in Finance, Accounting, a related field or equivalent directly related work
- 7-10 years of FP&A or Accounting experience
- Strong communication skills (oral, written and presentation)
- Able to build relationships across all functions and all levels of responsibility
- Robust finance/accounting background
- Expertise with MS Excel and PowerPoint
- Ability to work well both independently and as a team
- Possess an attention to detail to produce accurate work
- Financial owner for operational and capital budget related activities across the company
- Meet with functional leadership to understand expense drivers such as business changes and headcount assumptions
- Support functional leadership in managing P&L expenses, detailed analyses and budgeting
- Responsible for monthly forecast accuracy and reporting, headcount tracking, accruals and management reports
- Develop and maintain metrics that encourage data-driven decision making at the department level
- Assist in the enhancement and maintenance of company reporting tools
- Drive ad-hoc analyses and special projects
- MBA / Masters in Accounting or Finance a plus
- CPA/CMA a plus
- Medical Device, BioPharma or other Healthcare Technology experience is preferred
- SaaS business experience is a plus
- Knowledge of Planful, NetSuite and Tableau is a plus
HeartFlow provides a non-invasive cardiac test that helps doctors visualize a patient’s coronary arteries to diagnose and plan treatment for heart disease. It uses a proprietary set of analyses—FFRCT Analysis, RoadMap Analysis, Plaque Analysis, and HeartFlow Planner—to create a detailed, patient-specific visualization from imaging data, enabling clinicians to assess blood flow and plaque without surgery. This approach reduces the need for invasive procedures, lowers risk for patients, and can cut costs for healthcare providers. Compared with traditional methods, HeartFlow offers validated, FDA-cleared tools that integrate multiple analyses into one platform, giving physicians a clearer, data-driven basis for diagnosis and treatment decisions. The company’s goal is to improve cardiovascular care by making safer, more efficient diagnosis and treatment planning widely available in hospitals and clinics around the world.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Redwood City, California
Founded
2010
Simplify's Take
What believers are saying
- 2025 revenues hit $176M, up 40%, with 24-26% growth to $218-222M projected 2026.
- FISH&CHIPS delivers greater-than-modeled cost savings, boosting NHS and payer adoption.
- Capricorn's $48M stake and Bain's $419M investment signal strong investor confidence.
What critics are saying
- Ongoing $116.79M 2025 net losses exhaust cash, forcing dilutive financing by 2027.
- NHS cost scrutiny post-FISH&CHIPS slashes margins on $160.6M US revenues in 2026.
- Siemens Healthineers AI-CT rivals capture 30% US hospital contracts within 12 months.
What makes HeartFlow unique
- Lesion-specific FFRCT predicts MI and revascularization strongest in FISH&CHIPS 90,000-patient study.
- PCI Navigator integrates AI 3D models for pre-procedural stent planning launched October 2025.
- FFRCT combines anatomy, physiology, plaque analysis in personalized 3D heart models.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Stock Options
401(k) Company Match
Growth & Insights and Company News
6 month growth
↑ 2%1 year growth
↑ 2%2 year growth
↑ 1%Heartflow Inc. surged 27% week-on-week following its strong 2025 performance and optimistic growth guidance. The medical technology company reported 2025 revenues of $176 million, up 40% from $125.8 million in 2024, with US revenues rising 41% to $160.6 million and international revenues climbing 26% to $15.4 million. The company remains unprofitable, posting a net loss of $116.79 million, 21% higher than the previous year. However, fourth-quarter net loss decreased 26% to $24.4 million. For 2026, Heartflow projects revenue growth of 24% to 26%, targeting between $218 million and $222 million. CEO John Farquhar said the guidance "reflects strong business fundamentals" and expressed high confidence in consistent execution.
Capricorn Investment Group has purchased 1.7 million shares of HeartFlow, establishing a new position worth $48.18 million in the AI-powered cardiac diagnostics company, according to an SEC filing dated 17 February 2026. The stake represents 5.83% of Capricorn's reportable assets under management. HeartFlow offers AI-driven, non-invasive diagnostic solutions for coronary artery disease, generating revenue from healthcare providers and systems. The company went public in August 2025 and currently has a market capitalisation of $2.22 billion. As of 20 March 2026, HeartFlow shares traded at $26.30, down 10.7% year-to-date from a 52-week high of $41.22 reached last October. The company reported trailing twelve-month revenue of $161.88 million and a net loss of $125.37 million.
HeartFlow Inc is set to report Q4 2025 earnings on 18 March 2026. The consensus estimate projects revenue of $46.50 million and a loss of $0.27 per share. Full-year 2025 revenue is expected to reach $173.36 million, with a loss of $2.11 per share. Over the past 90 days, revenue estimates have increased slightly, whilst earnings estimates have declined. In Q3 2025, HeartFlow beat revenue expectations by 10.29% but missed earnings forecasts, posting a loss of $1.04 per share against an expected loss of $0.32 per share. The stock fell 13.43% following that release. Six analysts have set an average one-year price target of $38.50, suggesting an 83.51% upside from the current price of $20.98. The average brokerage recommendation is "Outperform".
HeartFlow, a medical technology company developing non-invasive diagnostics for coronary artery disease, will see its lock-up period expire on 4th February. The company issued 16,666,667 shares in its August public offering at $19.00 per share, raising $316.7 million. Following the expiry, restrictions preventing company insiders and major shareholders from selling shares will be lifted. Shares traded at $28.78 on Tuesday, giving the company a market capitalisation of $2.45 billion. HeartFlow has received positive analyst coverage, with five buy ratings, two hold ratings and one sell rating. The consensus price target stands at $38.50. The company's technology uses computational modelling to analyse coronary CT angiography data, creating three-dimensional physiological models to identify coronary lesions without invasive procedures.
Tulsa-based Schusterman Interests acquired 1.9 million shares of HeartFlow, Inc. for $65 million, making it the fourth-largest holding in their portfolio. HeartFlow, an AI-driven heart diagnostics company, saw its shares rise 70% from its $19 IPO price in August. The acquisition reflects confidence in HeartFlow's technology and potential for revenue growth. As of September 30, HeartFlow represented 14.9% of Schusterman's 13F assets.